A triple monoamine reuptake inhibitor that began life as a Parkinson's research compound and pivoted into metabolic research when scientists noticed unexpected effects on appetite signaling.
Tesofensine is a small molecule compound — technically not a peptide, but frequently studied alongside peptide research in the metabolic category because it acts on overlapping pathways. It was originally developed by NeuroSearch (a Danish pharmaceutical company) to investigate Alzheimer's disease and Parkinson's disease, where it was studied for its ability to modulate dopamine, serotonin, and norepinephrine levels in the brain.
During those neurological trials, researchers noticed something unexpected: subjects were experiencing significant changes in appetite and body weight. This pivoted Tesofensine's research trajectory toward metabolic science, where it has since been studied in multiple clinical trials for its effects on energy intake and metabolic regulation. It remains an investigational compound with no approved pharmaceutical indication, making it a valuable research tool for studying how neurotransmitter systems intersect with metabolic regulation.
📡 Weekly peptide research updates — regulatory updates, new compound profiles, COA alerts.
⚠️ FDA PCAC: -- days leftNo spam. Unsubscribe anytime. 7 peptides under review — see what's at stake →
Tesofensine is unique in metabolic research because it approaches appetite regulation from the central nervous system rather than from peripheral pathways like the gut hormone systems targeted by GLP-1 agonists.
7 free research tools built around exactly this kind of compound data. No paywall, no credit card.
Tesofensine inhibits the reuptake of dopamine, serotonin, and norepinephrine — three key neurotransmitters in the brain's reward and appetite-signaling circuits. By blocking reuptake, it keeps these neurotransmitters active in the synapse longer, amplifying their signals. In the context of appetite research, this is thought to reduce food-seeking behavior through multiple pathways simultaneously: dopamine affects reward circuits tied to eating, serotonin influences satiety signaling, and norepinephrine activates sympathetic pathways related to energy expenditure.
Imagine your brain has three different radio stations that broadcast "you're satisfied" signals. Most metabolic compounds tune one station at a time. Tesofensine turns up the volume on all three stations simultaneously. The brain hears the "satisfied" signal from more directions at once — which gives researchers a unique way to study how that multi-channel message gets processed compared to single-channel alternatives.
Research Disclaimer: The following reflects published clinical and preclinical research and is not medical advice. Consult a licensed healthcare provider before making any health decisions.
Tesofensine reached Phase IIb human clinical trials in obesity research — producing some of the most-cited early dose-finding data in the triple monoamine reuptake inhibitor field. Astrup et al. (2008, The Lancet) enrolled 203 participants with obesity in a 24-week, randomized, placebo-controlled trial, making it the most rigorous clinical data set available for this compound class.
Key References: Astrup A et al. (2008). "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial." The Lancet, 372(9653), 1906–1913. Sjödin A et al. (2010). "Tesofensine, a novel triple monoamine reuptake inhibitor, induces substantial weight loss in patients with severe obesity: a randomised, double-blind, placebo-controlled trial." Obesity (48-week extension data).
Tesofensine is a rare example of a compound that failed at its original research purpose and succeeded at something completely different — it missed as a neurological drug but generated significant interest in metabolic research. Drug repurposing is a real and productive part of pharmaceutical science.
Unlike GLP-1 agonists that work primarily through gut and peripheral signaling, Tesofensine acts directly in the brain — specifically in regions like the hypothalamus and nucleus accumbens that regulate hunger and reward. This makes it particularly valuable for studying the neuroscience of eating behavior.
The compound has been studied by multiple academic and pharmaceutical groups across Denmark, the US, and Brazil — making it one of the more internationally-studied metabolic research compounds in its class with data from multiple independent research teams.
Every batch of Tesofensine with full Certificate of Analysis documentation.